Three cholesterol drugs better than two for diabetics?

NCT ID NCT07255820

Completed Disease control Sponsor: Bahria University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 22, 2026 · Updated 2 times

Summary

This study tests whether taking three cholesterol-lowering drugs together works better than taking two in people with type 2 diabetes and high LDL cholesterol. 126 adults aged 35-60 will be split into three groups: one gets rosuvastatin plus ezetimibe, another gets bempedoic acid plus ezetimibe, and the third gets all three drugs. The goal is to see which combination lowers LDL cholesterol most safely over 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Rosuvastatin, Ezetimibe, Bempedoic Acid
What this could lead to: If triple therapy works better, it could offer a more effective way to lower cholesterol in people with diabetes, reducing heart disease risk.
What could go wrong: This is a small, short-term study (12 weeks) with only 126 participants. Results may not apply to everyone, and adding a third drug could increase side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERCHOLESTEROLEMIA / ELEVATED LDL CHOLESTEROL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Dyslipidemias Hypercholesterolemia Hyperlipoproteinemia Type II type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERCHOLESTEROLEMIA / ELEVATED LDL CHOLESTEROL TYPE 2 DIABETES MELLITUS

Contacts and locations

Locations

National Medical Center

Karachi, Sindh, 75500, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.